GABAergic molecular pathology in schizophrenia

精神分裂症的 GABA 分子病理学

基本信息

  • 批准号:
    7192398
  • 负责人:
  • 金额:
    $ 29.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-03-21 至 2009-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Prefrontal cortex (RFC) GABAergic interneurons are a major target for the molecular pathology associated with schizophrenia (SZ) morbidity; their alteration may contribute to the reduction of cortical neuropil, which is an important component of SZ pathophysiology. Cortical GABAergic neurons participate in the orchestration of cortical pyramidal neuron population firing via the release of GABA on GABAA and GABAB receptors and modulate dendritic spine plasticity via the translation of spine resident mRNAs facilitated by the GABAergic neuron release of reelin acting on integrin receptors located on dendritic spine postsynaptic densities. In SZ cortical GABAergic neurons, the synthesis of GABA and reelin is reduced because of a downregulation in GAQ67 and reelin mRNA expressions. Very probably this is due to an increased expression in GABAergic neurons of DNA-(cytosine 5)-methyltransferase1 (DNMT1) that contributes to the epigenetic hypermethylation of CpG islands and promoters expressed in reelin and GAD67 genes and to the consequent decreased synthesis of these two gene transcripts. Thus, we hypothesize that downregulation of GABAergic function due to an epigenetic mechanism may be an important primary process operative in SZ morbidity. We will study whether: 1) in addition to BA9 and BA10 GABAergic neurons, DNMT1 is coexpressed with reelin and GAD67, in the GABAergic neurons of the occipital cortex and caudate nucleus; 2) in every GABAergic neuron, the increase of DNMT1 expression coincides with a decrease of reelin and GAD67 expression; 3) the increase of DNMT1 and the decrease of reelin and GAD67 expression also extend to brains of bipolar disorder patients; 4) DNMT1 establishes a partnership with complexes including histone deacetylases and histone methylases, two prominent enzymes to regulate the code whereby histones control accessibility of transcription factors or DNMT1 to targeted regulatory sites in gene promoters. A better understanding of how epigenetic mechanisms can regulate reelin and GAD67 gene transcription may allow the discovery of new drug targets that can reprogram transcription and perhaps modify pathologies related to epigenetically-induced downregulation of gene expression in SZ.
描述(申请人提供):前额叶皮质(RFC)GABA能中间神经元是精神分裂症(SZ)发病相关分子病理学的主要靶点;它们的改变可能有助于皮质神经纤维的减少,这是SZ病理生理学的重要组成部分。皮质GABA能神经元通过GABAA和GABAB受体上GABA的释放参与皮质锥体神经元群体放电的协调,并通过GABA能神经元释放作用于树突棘突触后密度上整合素受体的reelin,通过翻译驻留在脊椎上的mRNAs来调节树突棘的可塑性。在SZ皮质GABA能神经元中,由于GAQ67和Reelin基因表达下调,GABA和reelin的合成减少。这很可能是由于GABA能神经元中DNA-(胞嘧啶5)-甲基转移酶1(DNMT1)的表达增加,导致Reelin和GAD67基因中表达的CpG岛和启动子的表观遗传超甲基化,从而导致这两个基因转录本的合成减少。因此,我们假设,由于表观遗传机制导致的GABA能功能下调可能是SZ发病的一个重要的主要过程。我们将研究:1)除了BA9和BA10 GABA能神经元外,DNMT1在枕叶皮质和尾状核的GABA能神经元中是否与reelin和GAD67共表达;2)在每个GABA能神经元中,DNMT1表达的增加与reelin和GAD67表达的降低是一致的;3)DNMT1的表达增加以及reelin和GAD67表达的降低也延伸到双相情感障碍患者的大脑;4)DNMT1与包括组蛋白脱乙酰酶和组蛋白甲基酶在内的复合体建立了合作伙伴关系,这两种酶可以调节密码,从而控制组蛋白可以控制转录因子或DMTN1对基因启动子中靶向调控位点的可及性。更好地理解表观遗传机制如何调控reelin和GAD67基因转录,可能会发现新的药物靶点,可以重新编程转录,或许还可以修改与表观遗传诱导的SZ基因表达下调相关的病理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERMINIO COSTA其他文献

ERMINIO COSTA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERMINIO COSTA', 18)}}的其他基金

GABAergic molecular pathology in schizophrenia
精神分裂症的 GABA 分子病理学
  • 批准号:
    7365158
  • 财政年份:
    2005
  • 资助金额:
    $ 29.39万
  • 项目类别:
GABAergic molecular pathology in schizophrenia
精神分裂症的 GABA 分子病理学
  • 批准号:
    6918287
  • 财政年份:
    2005
  • 资助金额:
    $ 29.39万
  • 项目类别:
GABAergic molecular pathology in schizophrenia
精神分裂症的 GABA 分子病理学
  • 批准号:
    7034548
  • 财政年份:
    2005
  • 资助金额:
    $ 29.39万
  • 项目类别:
Reelin and GAD67 Downregulation
Reelin 和 GAD67 下调
  • 批准号:
    6331018
  • 财政年份:
    2001
  • 资助金额:
    $ 29.39万
  • 项目类别:
Reelin and GAD67 Downregulation
Reelin 和 GAD67 下调
  • 批准号:
    6718469
  • 财政年份:
    2001
  • 资助金额:
    $ 29.39万
  • 项目类别:
Reelin and GAD67 Downregulation
Reelin 和 GAD67 下调
  • 批准号:
    6881176
  • 财政年份:
    2001
  • 资助金额:
    $ 29.39万
  • 项目类别:
Reelin and GAD67 Downregulation
Reelin 和 GAD67 下调
  • 批准号:
    6639207
  • 财政年份:
    2001
  • 资助金额:
    $ 29.39万
  • 项目类别:
Reelin and GAD67 Downregulation
Reelin 和 GAD67 下调
  • 批准号:
    6539160
  • 财政年份:
    2001
  • 资助金额:
    $ 29.39万
  • 项目类别:
MOLECULAR MECHANISMS OF DIAZEPAM TOLERANCE
地西泮耐受性的分子机制
  • 批准号:
    2635537
  • 财政年份:
    1997
  • 资助金额:
    $ 29.39万
  • 项目类别:
MOLECULAR MECHANISMS OF DIAZEPAM TOLERANCE
地西泮耐受性的分子机制
  • 批准号:
    2858049
  • 财政年份:
    1997
  • 资助金额:
    $ 29.39万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.39万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了